Position of the Transparency Council – Piasky (crovalimab)

At its meeting on 23 June 2025, the Transparency Council adopted position No. 77/2025 on the appraisal of drug Piasky (crovalimab) under the drug program: “Treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) (ICD-10 D59.5)”

Publication of the position >>